(Total Views: 503)
Posted On: 02/06/2022 9:28:15 PM
Post# of 36542
Hi Buildit. Joe mentioned many times throughout 2020 of a pending peer review for Ii-Key-SARS-COVID-19 vaccine. That could only be for the early part of the pre-clinical work, or a fuller look at the later human blood studies. So far, nothing has been revealed in Ahead Of Print in PubMed.
Generex went dark this past Summer, but it appears they were falling behind on bills before that. The eviction is one example. Generex also still owed money to the HJackson Foundation for the Phase II, which may be why Dr. Mittendorf and team kept writing new data for GP2 as time since first injection began, but stopped for AE37. Unfortunately, for us Gnbt shareholders, that meant we missed on otherwise opportunistic data reveals at ASCO or SABCS.
I don’t mean to make that sound negative. Money changes things. I recall Joe saying once that timelines are about funds. It’s true. Purcell really seemed to be doing well with all his work on the Covid vaccine. Hopefully, we see a peer review soon, or Generex awakes to start refunding vital projects.
Generex went dark this past Summer, but it appears they were falling behind on bills before that. The eviction is one example. Generex also still owed money to the HJackson Foundation for the Phase II, which may be why Dr. Mittendorf and team kept writing new data for GP2 as time since first injection began, but stopped for AE37. Unfortunately, for us Gnbt shareholders, that meant we missed on otherwise opportunistic data reveals at ASCO or SABCS.
I don’t mean to make that sound negative. Money changes things. I recall Joe saying once that timelines are about funds. It’s true. Purcell really seemed to be doing well with all his work on the Covid vaccine. Hopefully, we see a peer review soon, or Generex awakes to start refunding vital projects.
(8)
(0)Scroll down for more posts ▼
